HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 19, Issue 4, 2010, Pages 3-9

  Van De Vijver, David A M C ^a   Wensing, Annemarie M J ^b   Åsjö, Birgitta ^c   Bruckova, Marie ^d   Jorgensen, Louise Bruun ^e   Camacho, Ricardo ^f   Horban, Andrzej ^g   Linka, Marek ^d   Lazanas, Marios ^h   Loveday, Clive ⁱ   MacRae, Eilidh ⁱ   Nielsen, Claus ^e   Paraskevis, Dimitrios ^j   Poljak, Mario ^k   Puchhammer Stöckl, Elisabeth ^l   Ruiz, Lidia ^m   Schmit, Jean Claude ⁿ   Stanczak, Grzegorz ^g   Stanojevic, Maja ^o   Vandamme, Anne Mieke ^p   Vercauteren, Jurgen ^p   Zazzi, Maurizio ^q   Bacheler, Lee ^r   Lecocq, Pierre ^s   Villacian, Jorge ^s   Boucher, Charles A B ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF BERGEN   (Norway)

^d National Reference Laboratory on AIDS   (Czech Republic)

^e STATENS SERUM INSTITUT   (Denmark)

^f HOSPITAL EGAS MONIZ   (Portugal)

^g SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^h RED CROSS HOSPITAL   (Greece)

ⁱ International Clinical Virology Centre   (United Kingdom)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k Slovenian AIDS Reference Centre   (Slovenia)

^l UNIVERSITY OF VIENNA   (Austria)

^m IrsiCaixa Foundation   (Spain)

ⁿ CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^o UNIVERSITY OF BELGRADE   (Serbia)

^p REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^q UNIVERSITY OF SIENA   (Italy)

^r VircoLab Inc   (United States)

^s VircoBVBA ^*  (Belgium)

more..

Author keywords

Drug resistance; Drug resistance interpretation systems; Treatment failure

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; TREATMENT FAILURE;

ADULT; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, PROTEIN; TREATMENT FAILURE;

EID: 79953799570     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998 Nov 28;352(9142):1725-30.
2. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003 Dec 13;362(9400):2002-11. (Pubitemid 37548427)
3. Spread programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008 Mar 12;22(5):625-35.
4. van de Vijver DAMC, Wensing AMJ, Boucher CAB, et al. The epidemiology of transmission of drug resistant HIV-1. In: HIV Sequence Compendium 2006/2007: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. LA-UR 07-4826;2007:17-36.
5. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005 Sep 15;192(6):958-66. (Pubitemid 41266791)
6. Pillay D, Green H, Matthias R, et al. Estimating HIV-1 Drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005 Sep 15;192(6):967-73. (Pubitemid 41266792)
7. Costagliola D, Descamps D, Assoumou L, et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):12-8. (Pubitemid 47507429)
8. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis. 2005 Apr 15;191(8):1325-30.
9. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004 Jul 2;18(10):1393-401. (Pubitemid 38925131)
10. Scott P, Arnold E, Evans B, et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother. 2004 Mar;53(3):469-73.
11. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 2003 Nov 7;17(16):2383-8.
12. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006 Aug-Sep;14(3):125- 30.
13. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005 Oct 1;21(19):3797-800. (Pubitemid 41535530)
14. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007 Oct;145(1):47-55. (Pubitemid 47247892)
15. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411-9.
16. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type I. J Virol 2006 Jul;80(14):7020-7. (Pubitemid 44025200)
17. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005 Feb 1;191(3):339-47. (Pubitemid 40139758)
18. Torti C, Quiros-Roldan E, Keulen W, et al. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis. 2003 Jul 15;188(2):194-201. (Pubitemid 36898150)
19. Ravela J, Betts BJ, Brun-Vézinet F, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr. 2003 May 1;33(1):8-14. (Pubitemid 36547235)
20. van de Vijver DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006 Mar;41(3):352-60.